ClinicalTrials.gg
CompletedNCT00662857Updated Oct 16, 2014Results posted

A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro

A Phase 2 interventional study of Technosphere® Insulin Inhalation Powder and Technosphere Insulin® Inhalation Powder in Diabetes Mellitus: Type 1, sponsored by Mannkind Corporation. Completed at 2 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2014-10-16.

Sponsored by Mannkind Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 — 1 open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 1.

Enrollment
24th of 35
29 · median 74
Started
2008
with 2 others
Phase 2
8 of 35
1 open now
Registered
19th of 35
by date
Lead sponsor
14 of 35
Mannkind Corporation

Among the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, this one is the 24th largest by enrollment, is one of 3 that started in 2008, is one of 8 in phase 2, and was the 19th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

1 of the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Insulin, Regular, Human

Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

28 subjects to be enrolled for a screening period, 3 dosing visits \& a follow-up visit. Visits 2 and 3 dosing of TI Inhalation Powder, cross over between two 15 U cartridges and one 30 U cartridge. Visit 4 dosing will be a sc injection of 10 IU of RAA (rapid-acting insulin analogue).

Read the detailed description

28 eligible subjects were planned to be enrolled to determine bioequivalence and safety parameters of two 15 U TI Inhalation Powder cartridges versus one 30 U TI Inhalation Powder cartridge, according to a randomized, 2-way crossover design. Additionally, bioavailability of one 30 U TI Inhalation Powder cartridge to a single subcutaneous injection of 10 IU of RAA will be compared.

03

Conditions studied

  • Diabetes Mellitus: Type 1

Keywords

  • Diabetic adult male, diabetic adult female
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Males and Females > 18 and \< 60 years of age Clinical diagnosis of type 1 diabetes mellitus with stable anti-diabetic regimen for at least 90 days prior to Screening of \< 30 kg/m2 Non-smokers (never smoked or former smokers (> 6 months since cessation) Pulmonary Function Testing ( > 70%, FEV1/FVC > 70%, TLC > 80% DLco [unc] > 70% of Predicted Written

Exclusion criteria

Exclusion Criteria:

Two or more severe hypoglycemic episodes within 6 months of Screening/Visit 1 Severe complications of diabetes Previous exposure to any inhaled insulin product other than TI inhalation Powder or similar formulation Inability to perform PFT maneuvers meeting recommended American Thoracic Society (ATS) standards of acceptability and repeatability criteria Respiratory tract infection within 8 weeks prior to Screening/Visit 1 History of (COPD), clinically proven asthma, and/or any other pulmonary disease (eg. Obstructive sleep apnea), confirmed by pulmonary function testing, and/or radiologic findings Major organ system diseases including seizures, heart failure, uncontrolled hypertension, cancer within the past 5 years, liver disease, anemia or disorder Clinically significant abnormalities on screening laboratory evaluation Female subjects who are pregnant, lactating, or planning to become pregnant during the clinical trial period or not practicing adequate Unable and/or unlikely to comprehend how to use the device in this study or to follow study instructions

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    1: TI Inhalation Powder A

    Technosphere® Insulin Inhalation Powder, two 15 U cartridges

    Drug: Technosphere® Insulin Inhalation Powder

  • Experimental
    2: TI Inhalation Powder B

    Technosphere® Insulin Inhalation Powder, one 30 U cartridge

    Drug: Technosphere Insulin® Inhalation Powder

  • Experimental
    3: RAA Population

    Rapid Acting Analogue subjects received 10 IU sc Insulin Lispro

    Drug: RAA Population

Interventions

06

What researchers measure

Primary outcomes

  1. Bioequivalence of Two 15 U Cartridges (TI Inhalation Powder A) and One 30 U Cartridge (TI Inhalation Powder B) Based on Baseline Corrected Insulin AUC0-360

    Dose-normalized baseline-corrected area under the serum insulin vs. time curve

    Time frame: 0 to 360 minutes post-dose

  2. Bioequivalence of Two 15 U Cartridges (TI Inhalation Powder A) and One 30 U Cartridge (TI Inhalation Powder B) Based on Baseline Corrected Insulin Cmax.

    Maximum observed baseline-corrected serum insulin concentration

    Time frame: 0 to 360 minutes post-dose

  3. Bioequivalence of Two 15 U Cartridges (TI Inhalation Powder A) and One 30 U Cartridge (TI Inhalation Powder B) Based on Baseline Corrected Insulin Tmax

    Time frame: 0 to 360 minutes post-dose

  4. Relative Bioavailability of 30 U of TI (TI Inhalation Powder B) Versus 10 U of sc Insulin Lispro

    Dose-normalized baseline-corrected area under the serum insulin vs. time curve (time 0 to 360 minutes post-dose)

    Time frame: 0 to 360 minutes post-dose

07

Results

Posted Oct 16, 2014

Participant flow

This was a single site with first subject screened 24 Apr 2008

TI Dosing Period 1 (1 Day)
Participant flow — TI Dosing Period 1 (1 Day)
MilestoneTI - A (2x15 U)/TI - B (1x30 U)/10 U sc Insulin LisproTI - B (1x30 U)/TI - A (2x15 U)/10 U sc Insulin Lispro
Started1316
Completed1316
Not completed00
Washout 1 (3 - 14 Days)
Participant flow — Washout 1 (3 - 14 Days)
MilestoneTI - A (2x15 U)/TI - B (1x30 U)/10 U sc Insulin LisproTI - B (1x30 U)/TI - A (2x15 U)/10 U sc Insulin Lispro
Started1316
Completed1314
Not completed02
Withdrew: Physician decision01
Withdrew: Withdrawal by subject01
TI Dosing Period 2 (1 Day)
Participant flow — TI Dosing Period 2 (1 Day)
MilestoneTI - A (2x15 U)/TI - B (1x30 U)/10 U sc Insulin LisproTI - B (1x30 U)/TI - A (2x15 U)/10 U sc Insulin Lispro
Started1314
Completed1314
Not completed00
Washout 2 (3 - 14 Days)
Participant flow — Washout 2 (3 - 14 Days)
MilestoneTI - A (2x15 U)/TI - B (1x30 U)/10 U sc Insulin LisproTI - B (1x30 U)/TI - A (2x15 U)/10 U sc Insulin Lispro
Started1314
Completed1214
Not completed10
Withdrew: Cannot use clamp data10
Lispro Dosing Period (1 Day)
Participant flow — Lispro Dosing Period (1 Day)
MilestoneTI - A (2x15 U)/TI - B (1x30 U)/10 U sc Insulin LisproTI - B (1x30 U)/TI - A (2x15 U)/10 U sc Insulin Lispro
Started1214
Completed1214
Not completed00

Outcome measures

PrimaryBioequivalence of Two 15 U Cartridges (TI Inhalation Powder A) and One 30 U Cartridge (TI Inhalation Powder B) Based on Baseline Corrected Insulin AUC0-360

Dose-normalized baseline-corrected area under the serum insulin vs. time curve

Time frame:
0 to 360 minutes post-dose
Reported as:
Least squares mean · (micro U)*min/mL
Bioequivalence of Two 15 U Cartridges (TI Inhalation Powder A) and One 30 U Cartridge (TI Inhalation Powder B) Based on Baseline Corrected Insulin AUC0-360
(micro U)*min/mLTechosphere Insulin - A (2 x 15 U)Techosphere Insulin - B (1 x 30 U)
Bioequivalence of Two 15 U Cartridges (TI Inhalation Powder A) and One 30 U Cartridge (TI Inhalation Powder B) Based on Baseline Corrected Insulin AUC0-3603337.2 ± 1.0963396.6 ± 1.096
Statistical analysis
  • Techosphere Insulin - A (2 x 15 U) vs Techosphere Insulin - B (1 x 30 U) · Ratio of geometric means: 0.982 · 90% CI 0.846 to 1.141Geometric Mean Ratio of serum insulin from a single 30 U cartridge to 2 x 15 U cartridges of TI. Based on pair-wise comparisons from analysis of covariance fitting the model: natural log of parameter = cohort, treatment, visit, subject (cohort).
PrimaryBioequivalence of Two 15 U Cartridges (TI Inhalation Powder A) and One 30 U Cartridge (TI Inhalation Powder B) Based on Baseline Corrected Insulin Cmax.

Maximum observed baseline-corrected serum insulin concentration

Time frame:
0 to 360 minutes post-dose
Reported as:
Least squares mean · (micro U)/mL
Bioequivalence of Two 15 U Cartridges (TI Inhalation Powder A) and One 30 U Cartridge (TI Inhalation Powder B) Based on Baseline Corrected Insulin Cmax.
(micro U)/mLTechosphere Insulin - A (2 x 15 U)Techosphere Insulin - B (1 x 30 U)
Bioequivalence of Two 15 U Cartridges (TI Inhalation Powder A) and One 30 U Cartridge (TI Inhalation Powder B) Based on Baseline Corrected Insulin Cmax.65.72 ± 1.09869.08 ± 1.098
Statistical analysis
  • Techosphere Insulin - A (2 x 15 U) vs Techosphere Insulin - B (1 x 30 U) · Ratio of geometric means: 0.951 · 90% CI 0.823 to 1.099Geometric Mean Ratio of serum insulin from a single 30 U cartridge to 2 x 15 U cartridges of TI. Based on pair-wise comparisons from analysis of covariance fitting the model: natural log of parameter = cohort, treatment, visit, subject (cohort).
PrimaryBioequivalence of Two 15 U Cartridges (TI Inhalation Powder A) and One 30 U Cartridge (TI Inhalation Powder B) Based on Baseline Corrected Insulin Tmax
Time frame:
0 to 360 minutes post-dose
Reported as:
Median · min
Bioequivalence of Two 15 U Cartridges (TI Inhalation Powder A) and One 30 U Cartridge (TI Inhalation Powder B) Based on Baseline Corrected Insulin Tmax
minTechosphere Insulin - A (2 x 15 U)Techosphere Insulin - B (1 x 30 U)
Bioequivalence of Two 15 U Cartridges (TI Inhalation Powder A) and One 30 U Cartridge (TI Inhalation Powder B) Based on Baseline Corrected Insulin Tmax10 (5 to 24)10 (5 to 20)
Statistical analysis
  • Techosphere Insulin - A (2 x 15 U) vs Techosphere Insulin - B (1 x 30 U) · Signed Rank Test · p = 0.3531 · Median difference (final values): 0
PrimaryRelative Bioavailability of 30 U of TI (TI Inhalation Powder B) Versus 10 U of sc Insulin Lispro

Dose-normalized baseline-corrected area under the serum insulin vs. time curve (time 0 to 360 minutes post-dose)

Time frame:
0 to 360 minutes post-dose
Reported as:
Least squares mean · (micro U)*min/mL
Relative Bioavailability of 30 U of TI (TI Inhalation Powder B) Versus 10 U of sc Insulin Lispro
(micro U)*min/mLTechosphere Insulin - B (1 x 30 U)10 U Subcutaneous (sc) Insulin Lispro
Relative Bioavailability of 30 U of TI (TI Inhalation Powder B) Versus 10 U of sc Insulin Lispro3406.8 ± 1.0957404.0 ± 1.102
Statistical analysis
  • Techosphere Insulin - B (1 x 30 U) vs 10 U Subcutaneous (sc) Insulin Lispro · Ratio of geometric means: 0.460 · 90% CI 0.366 to 0.578Geometric Mean Ratio of serum insulin from a single 30 U cartridge of TI to 10 U sc insulin lispro. Based on pair-wise comparisons from analysis of covariance fitting the model: natural log of parameter = cohort, treatment, visit, subject (cohort).

Adverse events

Collected over From time of first dose to 30d after last dose; Serious adverse event (SAE) = until resolution. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Techosphere Insulin - A (2 x 15 U)—0/27 (0%)9/27 (33.3%)
Techosphere Insulin - B (1 x 30 U)—0/29 (0%)14/29 (48.3%)
10 U Subcutaneous (sc) Insulin Lispro—0/26 (0%)5/26 (19.2%)
Most frequent other events
Most frequent other events
EventTechosphere Insulin - A (2 x 15 U)Techosphere Insulin - B (1 x 30 U)10 U Subcutaneous (sc) Insulin Lispro
CoughRespiratory, thoracic and mediastinal disorders4/277/290/26
HeadacheNervous system disorders2/275/291/26
HypoglycaemiaMetabolism and nutrition disorders1/274/291/26
Hepatic enzyme increasedInvestigations0/270/292/26
NauseaGastrointestinal disorders2/271/291/26

Baseline characteristics

Age, Continuous
Age, Continuous(years)Safety Population
Mean37.4 ± 12.71
Sex: Female, Male
Sex: Female, Male(Participants)Safety Population
Female10
Male19
Body mass index (BMI)
Body mass index (BMI)(kg/m squared)Safety Population
Mean26.61 ± 2.772
08

Study locations

2 sites
  • Profil Institute for Clinical Research Inc.
    Chula Vista, California 91911, United States
  • Diabetes & Glandular Disease Research Assoc PA
    San Antonio, Texas 78229, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Nov 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 5 years 11 months after primary completion. A results delay was requested in Jun 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2008
First posted
Apr 21, 2008
Start
Apr 2008
Primary completionActual
Nov 2008
CompletionActual
Dec 2008
Results delay requested
Jun 9, 2009
Results first posted
Oct 16, 2014
Last update
Oct 16, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00662857
Responsible party
Sponsor
First posted
Apr 21, 2008
Start date
Apr 2008
Primary completion
Nov 2008
Completion
Dec 2008
Results posted
Oct 16, 2014
Last update
Oct 16, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin, Regular, Human

Start the discussion